AI Engines For more Details: Perplexity Kagi Labs You
Seizure Control: Ethotoin is effective in controlling seizures by reducing abnormal electrical activity in the brain. It is particularly useful for treating tonic-clonic seizures and complex partial seizures, both as monotherapy and as adjunctive therapy with other antiepileptic drugs.
Epilepsy: Ethotoin is indicated for the management of epilepsy, a neurological disorder characterized by recurrent seizures. It helps prevent or reduce the frequency and severity of seizures in individuals with epilepsy.
Off-Label Uses: In some cases, ethotoin may be used off-label to treat other types of seizures or neurological conditions, although its primary use is in the management of generalized and partial seizures.
Dosage Adjustment: The dosage of ethotoin may need to be adjusted based on individual response, seizure control, and tolerability. It is important for patients to follow their healthcare provider's instructions regarding dosage and administration.
Side Effects: Common side effects of ethotoin may include drowsiness, dizziness, headache, nausea, vomiting, loss of appetite, and skin rash. More serious side effects such as liver problems, blood disorders, and allergic reactions are possible but less common.
Drug Interactions: Ethotoin may interact with other medications, including anticoagulants, oral contraceptives, and certain antiepileptic drugs, affecting their effectiveness or increasing the risk of side effects. It is important for patients to inform their healthcare provider about all medications they are taking.
Monitoring: Patients taking ethotoin may require regular monitoring of blood levels to ensure therapeutic efficacy and minimize the risk of toxicity. Blood tests may also be needed to assess liver function and hematological parameters.
Pregnancy and Breastfeeding: Ethotoin should be used with caution in pregnant women, as it may pose risks to the developing fetus. It may also be excreted in breast milk, so breastfeeding mothers should discuss the risks and benefits with their healthcare provider.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.4 | -0.33 |
| ADHD | 3.2 | 0.6 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 1.6 | 0.75 |
| Allergies | 4.8 | 2.5 | 0.92 |
| Allergy to milk products | 1.5 | 1.6 | -0.07 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 5.9 | 3.5 | 0.69 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.7 | 1.71 |
| Ankylosing spondylitis | 3.1 | 1 | 2.1 |
| Anorexia Nervosa | 1.5 | 2.1 | -0.4 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
| Asthma | 4.1 | 1.8 | 1.28 |
| Atherosclerosis | 2 | 0.9 | 1.22 |
| Atrial fibrillation | 2.6 | 1.9 | 0.37 |
| Autism | 5.9 | 5.6 | 0.05 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.2 | 2.2 | |
| Bipolar Disorder | 2.4 | 1.4 | 0.71 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.3 | 0.3 | 3.33 |
| Cancer (General) | 0.9 | 0.3 | 2 |
| Carcinoma | 4.8 | 2.5 | 0.92 |
| Celiac Disease | 1.8 | 2.8 | -0.56 |
| Cerebral Palsy | 1.4 | 1.1 | 0.27 |
| Chronic Fatigue Syndrome | 3.4 | 2.6 | 0.31 |
| Chronic Kidney Disease | 3 | 1.3 | 1.31 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.4 | 0.5 |
| Chronic Urticaria (Hives) | 1.8 | 0.2 | 8 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1.1 | 0.55 |
| Cognitive Function | 3 | 1.6 | 0.88 |
| Colorectal Cancer | 6.9 | 2.6 | 1.65 |
| Constipation | 1.3 | 1.2 | 0.08 |
| Coronary artery disease | 2 | 1.6 | 0.25 |
| COVID-19 | 5.7 | 4.5 | 0.27 |
| Crohn's Disease | 6.7 | 3.5 | 0.91 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1 | 1.3 | -0.3 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.6 | 1.4 | 0.86 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 6.6 | 5 | 0.32 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.4 | 0.29 |
| Endometriosis | 2.8 | 1.8 | 0.56 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.8 | 1.2 | 1.33 |
| erectile dysfunction | 1.6 | 0.3 | 4.33 |
| Fibromyalgia | 2.6 | 0.8 | 2.25 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 2.4 | 0.54 |
| gallstone disease (gsd) | 3.1 | 1.1 | 1.82 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.3 | 3.67 |
| Generalized anxiety disorder | 2.3 | 1.6 | 0.44 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 0.5 | 1.4 |
| Graves' disease | 1.9 | 2.9 | -0.53 |
| Gulf War Syndrome | 0.5 | 0.5 | 0 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 2.9 | 1 | 1.9 |
| Heart Failure | 3.2 | 1.1 | 1.91 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.9 | |
| hyperglycemia | 1.5 | 1 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 3.4 | 2.7 | 0.26 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.9 | 2 | -0.05 |
| Inflammatory Bowel Disease | 5.9 | 4.4 | 0.34 |
| Insomnia | 2.1 | 1.7 | 0.24 |
| Intelligence | 0.9 | 0.9 | |
| Intracranial aneurysms | 1.3 | 0.6 | 1.17 |
| Irritable Bowel Syndrome | 5.7 | 3.4 | 0.68 |
| ischemic stroke | 2.3 | 1.4 | 0.64 |
| Liver Cirrhosis | 6.1 | 3.7 | 0.65 |
| Long COVID | 3.8 | 4.5 | -0.18 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.9 | 0.9 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.6 | 1.5 |
| ME/CFS with IBS | 0.6 | 0.7 | -0.17 |
| ME/CFS without IBS | 1.1 | 1.3 | -0.18 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.8 | 0.5 | 0.6 |
| Metabolic Syndrome | 6.3 | 4.6 | 0.37 |
| Mood Disorders | 5.9 | 4.6 | 0.28 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 5.5 | 2.9 | 0.9 |
| Multiple system atrophy (MSA) | 0.5 | 0.6 | -0.2 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.4 | -3.67 |
| Neuropathy (all types) | 0.6 | 2.3 | -2.83 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.5 | 1.9 | 1.37 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.6 | 1 |
| Obesity | 6.3 | 5.5 | 0.15 |
| obsessive-compulsive disorder | 3 | 2 | 0.5 |
| Osteoarthritis | 1.6 | 1.2 | 0.33 |
| Osteoporosis | 2.5 | 1.2 | 1.08 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 5.6 | 4.5 | 0.24 |
| Polycystic ovary syndrome | 4 | 2.6 | 0.54 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2.4 | 1.2 | 1 |
| Psoriasis | 2.7 | 1.4 | 0.93 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.8 | 3.2 | 0.81 |
| Rosacea | 0.7 | 1 | -0.43 |
| Schizophrenia | 4 | 2.3 | 0.74 |
| scoliosis | 0.4 | 0.6 | -0.5 |
| Sjögren syndrome | 2.1 | 1.7 | 0.24 |
| Sleep Apnea | 1.5 | 1.4 | 0.07 |
| Slow gastric motility / Gastroparesis | 1.3 | 0.3 | 3.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
| Stress / posttraumatic stress disorder | 3 | 2 | 0.5 |
| Systemic Lupus Erythematosus | 3.6 | 2 | 0.8 |
| Tic Disorder | 1 | 1.2 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.5 | 2.2 | 0.59 |
| Type 2 Diabetes | 6.6 | 5 | 0.32 |
| Ulcerative colitis | 4.7 | 3.3 | 0.42 |
| Unhealthy Ageing | 3.5 | 1.6 | 1.19 |
| Vitiligo | 1.8 | 0.9 | 1 |
